CureVac N.V. - Ordinary Shares (NQ:CVAC)

4.660 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CureVac N.V. - Ordinary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

February 16, 2022

We've got another busy day of trading ahead of us so let's get right to it with the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

February 15, 2022

We've got another busy day of trading ahead of us and we're starting with the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

February 10, 2022

- Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains - Influenza candidate developed in collaboration with GSK within broad...

From CureVac

Via AccessWire

Why CureVac Shares Are Falling ↗

October 15, 2021

CureVac BV (NASDAQ: CVAC) shares are trading lower after the company and Bayer reportedly terminated their vaccine manufacturing partnership. More news came around 1:20 pm...

Via Benzinga

53 Biggest Movers From Friday ↗

January 24, 2022

Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares climbed 100% to close at $3.80 on Friday after gaining around 9% on Thursday. Dave Inc. (NASDAQ: DAVE) jumped 30.3% to settle...

Via Benzinga

CVAC Stock Alert: Why Is Vaccine Maker CureVac Plunging Today? ↗

January 21, 2022

Amid broadly bearish market sentiment, investors in CureVac and CVAC stock are in selling mode, as this stock receives a downgrade.

Via InvestorPlace

34 Stocks Moving In Friday's Mid-Day Session ↗

January 21, 2022

Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares jumped 180% to $5.32 after gaining around 9% on Thursday. Bon Natural Life Limited (NASDAQ: BON) shares gained 22% to $3.91....

Via Benzinga

BofA Downgrades CureVac On Limited 2022 Prospects ↗

January 21, 2022

There is limited upside from CureVac BV’s (NASDAQ:CVAC

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 21, 2022 ↗

January 21, 2022

Upgrades According to Seaport Global, the prior rating for KB Home (NYSE:

Via Benzinga

Chopped Stocks ↗

January 18, 2022

The day's theme is sell tech and buy banks.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022 ↗

January 18, 2022

Upgrades Canaccord Genuity upgraded the previous rating for Fortuna Silver Mines Inc (NYSE:

Via Benzinga

52 Biggest Movers From Friday ↗

January 18, 2022

Gainers Splash Beverage Group, Inc. (NASDAQ: SBEV) shares gained 118.9% to settle at $4.18 on Friday. Splash Beverage recently announced it has received authorization to sell its...

Via Benzinga

CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

January 17, 2022

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 17, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...

From CureVac

Via AccessWire

30 Stocks Moving In Friday's Mid-Day Session ↗

January 14, 2022

Gainers ATI Physical Therapy, Inc. (NYSE: ATIP) shares gained 25.2% to $3.8050 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $3.50 to $5....

Via Benzinga

dievini and the Federal Republic of Germany Amend Shareholders’ Agreement Regarding Investments in CureVac N.V.

January 13, 2022

BERLIN, GERMANY / ACCESSWIRE / January 13, 2022 / Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt für...

From dievini Hopp BioTech holding GmbH & Co. KG

Via AccessWire

CureVac Outlines Upcoming Catalysts For Vaccine Programs ↗

January 10, 2022

Ahead of J.P. Morgan Healthcare Conference, CureVac BV (NASDAQ: CVAC) outlined the timeline for its vaccine programs. CureVac's preclinical second-...

Via Benzinga

The 'Highly Mutated Virus' Signals A Need For Annual Shots: BioNTech CEO ↗

December 03, 2021

The omicron variant signals a need for annual Covid shots, BioNTech's CEO said.

Via Investor's Business Daily

56 Biggest Movers From Friday ↗

November 29, 2021

Gainers iSpecimen Inc. (NASDAQ: ISPC) climbed 71.7% to settle at $17.51 on Friday. The company recently announced it has been contracted to support new advanced research on...

Via Benzinga

48 Stocks Moving In Friday's Mid-Day Session ↗

November 26, 2021

Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares jumped 68% to $9.04. Shares of mask and protective apparel companies, including Allied Healthcare Products, traded...

Via Benzinga

CureVac (CVAC) Q3 2021 Earnings Call Transcript ↗

November 19, 2021

CVAC earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update

November 19, 2021

- Strategic focusing on second-generation mRNA program jointly developed with GSK after withdrawal of first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review - Nature publication of...

From CureVac

Via AccessWire

Topics Death Intellectual Property Regulatory Compliance

CureVac's COVID-19 Vax Shows Comparable Antibody Levels To Pfizer/BioNTech's Shot In Animal Study ↗

November 18, 2021

CureVac BV (NASDAQ: CVAC) has announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with...

Via Benzinga

The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings ↗

November 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia...

Via Benzinga

CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

November 18, 2021

TÜBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / November 18, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...

From CureVac

Via AccessWire

Topics Intellectual Property Regulatory Compliance

CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response

November 10, 2021

- Immune profiling of clinical trial participants in Phase 1 dose-escalation study shows immune response in both injected and non-injected lesions - Expansion part of Phase 1 study fully recruited;...

From CureVac

Via AccessWire

Topics Intellectual Property Regulatory Compliance

Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage ↗

October 18, 2021

Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral...

Via Talk Markets

Why CureVac Stock Is Tumbling Today ↗

October 12, 2021

The company is throwing in the towel on its first-generation COVID-19 vaccine candidate.

Via The Motley Fool

Why CureVac Shares Are Trading Lower Today ↗

October 12, 2021

CureVac NV (NASDAQ: CVAC) is trading lower Tuesday after the company announced it will focus its COVID-19 vaccine development towards the development of second-gen mRNA...

Via Benzinga

51 Biggest Movers From Friday ↗

October 18, 2021

Gainers LM Funding America, Inc. (NASDAQ: LMFA) shares jumped 38.1% to close at $4.75 on Friday after declining around 15% on Thursday. The company recently announced it...

Via Benzinga

CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology

October 12, 2021

- COVID-19 vaccine efforts to be re-allocated to accelerate the development of second-generation program in collaboration with GSK - First-generation vaccine candidate, CVnCoV, to be withdrawn from...

From CureVac

Via AccessWire

Topics Intellectual Property Regulatory Compliance

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.